Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Brexit Rare Diseases Deals

Podcast: Woodford’s UK Biotech Fallout, Rare Disease Deals and Brexit

The Low-Down On Big Biopharma Stories

Executive Summary

Scrip's Kevin Grogan and Andrew McConaghie try out the padded cell/recording studio at Informa HQ in London, giving their take on three hot topics from biopharma and healthcare.

A pilot edition podcast from Scrip’s Kevin Grogan and Andrew McConaghie, with a special focus on developments in UK and European biopharma and healthcare.

 

Scrip Podcast

Pilot episode

 

Open Media

 

Woodford's biotech fallout, rare disease deals, Brexit

 

Covering the fall of former star fund manager Neil Woodford, analysis of a recent spate of big licensing deals in the rare disease space, plus insights on what Brexit will mean for the UK life sciences sector in the long term.
 
Please give us feedback on this pilot episode – any comments on guests to invite or topics to cover gratefully received. Email a[email protected] k[email protected]
Table

View full table

Topics

Tags:
Brexit Rare Diseases Deals
Latest Headlines

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

See All
UsernamePublicRestriction

Register

SC126067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By